Clinical Trial Update: Intralipid® 20% for Reversal of Local Anesthetics [Phase 4]

View source ↗

Summary

This document reports an update on a Phase 4 clinical trial evaluating Intralipid 20% as a reversal agent for local anesthetic toxicity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Local Anesthetic Systemic Toxicity

Drugs mentioned

• Intralipid 20% (intravenous lipid emulsion 20%)

Snippet

Sponsor: Hospital for Special Surgery, New York | Conditions: Anesthesia, Local | Phase 4 | Status: ACTIVE_NOT_RECRUITING